uniQure Faces Securities Fraud Lawsuit Over Huntington's Gene Therapy Misstatements
Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.
QUREsecurities fraudclass action lawsuit